TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03292042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical health promotion program
Description: The program has 24 sessions. Each session has two parts:~* first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~* Second part: 1 hour of physical activity (walk)
Study: NCT02380521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (BYDUREON™)
Description: Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg
Study: NCT04370847

Intervention type: RADIATION
Intervention: lung ultrasound scans
Description: lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
Study: NCT01815437

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2 - Ergocalciferol
Description: 2000 IU vitamin D2, ergocalciferol once/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mushroom Extract
Description: Same quantity of mushroom extract in a capsule
Study: NCT04370847

Intervention type: OTHER
Intervention: Ultrasound Assessment of the Inferior Vena Cava
Description: The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
Study: NCT04958564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCP
Description: 1. Dynamic compression plating to compress the fracture~2. Intramedullary device to share the load.
Study: NCT04370847

Intervention type: OTHER
Intervention: Optic nerve sheath diameter
Description: Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.

Intervention type: DRUG
Intervention: ringer acetate
Description: 1000 ml ringer acetate will be administered over 2 hours.

Intervention type: DRUG
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.

Intervention type: DRUG
Intervention: Intravenous Syntocinon
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
Study: NCT02893254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI303
Description: 12 cycles. IBI303: 40 mg, iH
Study: NCT03641677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centralized Lung Evaluation System
Description: Assessment of allograft lung for transplant suitability

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Transplant
Description: Orthotopic single or double lung transplantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Transplant
Description: Orthotopic single or double lung transplantation.
Study: NCT04346238

Intervention type: OTHER
Intervention: Reuse of existing data from patients' medical records
Description: Reuse of existing data from patients' medical records
Study: NCT02217007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC-102 sustained release tablet
Description: SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
Study: NCT03555045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conducting the slanted recession technique on the superior and inferior poles
Description: conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conducting the augmented recession technique on the muscle
Description: conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
Study: NCT02893254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 12 cycles. Adalimumab: 40mg, iH
Study: NCT03224637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
Study: NCT01450267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Reduced Glutathione
Description: 10 mg/kg, twice daily, 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological solution
Description: 0,13 ml/kg body weight, twice daily, 12 months
Study: NCT05954663

Intervention type: OTHER
Intervention: Basic demographic information
Description: Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~* Clinical examination carried out 1 month after the operation and more than 6 months after the operation~* Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation
Study: NCT00744419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose \[0.4 mg/kg (\< 44 wks PMA) or 0.8 mg/kg (44 wks to \< 1 yr)\] and the last 6 subjects in each age group will receive high dose \[0.8 mg/kg(\< 44 wks PMA) or 1.6 mg/kg(44 wks to \< 1 yr)\]
Study: NCT04534621

Intervention type: OTHER
Intervention: Electronic survey
Description: Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
Study: NCT05891522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: portable scanner
Description: performing a portable cranial scanner on cerebro-injured intensive care patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixed scanner
Description: performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
Study: NCT03224637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (conventional)
Study: NCT00004931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT02697682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection with the stromal vascular fraction (SVF) of adipose tissue
Description: Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
Study: NCT03811145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tendoncel
Description: Platelet lysate gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control gel
Description: Placebo control gel
Study: NCT01601353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Genesis Cell Isolation System
Description: Liposuction followed by injection of autologous adipose derived cells
Study: NCT00004931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01827696

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ginseng
Description: Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
Study: NCT00004931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02166762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLV interval measurement
Description: Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
Study: NCT02203786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol.
Study: NCT02278302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Study: NCT02203786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluphenazine
Description: Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexedrine
Description: Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine.
Study: NCT02278302

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Study: NCT02203786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexedrine
Description: Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slot Machine
Description: 15 minute play of a commercial slot machine game in bar-simulated laboratory setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slot Machine
Description: 15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
Study: NCT04494607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lowest Glycemic Index for a selected type fo cereal product
Description: determination of lowest Glycemic Index for a selected type fo cereal product
Study: NCT02705573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
Study: NCT00756314

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Personalized contraceptive counseling
Description: The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized contraceptive counseling
Description: The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
Study: NCT02882893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium Botulinum A Toxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum A Toxin
Study: NCT03495895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minding the Baby
Description: Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care condition
Study: NCT04073303

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
Study: NCT00146107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 10 percent weight loss through diet and behavioral modification

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Multicomponent (resistance, aerobic, balance) exercise three times a week
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150
Study: NCT00146107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss and Exercise
Description: 10% weight loss through diet and exercise plus multicomponent exercise training three times a week
Study: NCT03860883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide Local Excision = 1cm Margin
Description: A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150
Study: NCT03860883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Local Excision = 2cm Margin
Description: A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.
Study: NCT02873403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KNEEMO knee brace
Description: Bespoke knee brace made by additive manufacturing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KNEEMO knee brace
Description: Bespoke knee brace made by additive manufacturing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Popular knee brace
Description: Customized knee brace used in the management of medial knee ostearthritis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Popular knee brace
Description: Customized knee brace used in the management of medial knee ostearthritis
Study: NCT04637828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561
Description: study drug
Study: NCT02272387

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Study: NCT02499328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150
Study: NCT02272387

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01178827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trospium chloride
Description: trospium chloride (60mg) once daily for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin IR
Description: oxybutynin IR (5 mg) three times daily for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxybutynin IR placebo
Description: oxybutynin IR placebo three times daily for 2 days
Study: NCT03923985

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic containing Lactobacillus Crispatus
Description: 1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
Study: NCT03224637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine (conventional)
Study: NCT04187001

Intervention type: OTHER
Intervention: Content Validity
Description: Use Delphi technique for achieve consensus

Intervention type: OTHER
Intervention: Cultural adaptation
Description: Adapt the content to the target population
Study: NCT04701255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification with intraocular lens implantation
Description: treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification with intraocular lens implantation
Description: treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocular aberrometer assesment
Description: evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocular aberrometer assesment
Description: evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
Study: NCT01038492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: p16 Methylation and Lung Cancer Education
Description: * patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~* patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits.
Study: NCT04260724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: * stimulation intensity : motor threshold 100%~* stimulation frequency : 1600 pulses for 20 minutes~* stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham coil stimulation
Description: no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
Study: NCT02227407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGOs(reciprocating gait orthoses)
Description: using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
Study: NCT04559672

Intervention type: PROCEDURE
Intervention: Cervical laminoplasty surgery
Description: The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation

Intervention type: PROCEDURE
Intervention: Cervical laminectomy and fusion surgery
Description: The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
Study: NCT01433081

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion of .9 normal saline
Description: administration of .9 normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of magnesium sulfate
Description: administration of magnesium sulfate